Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

@article{Rowinsky1995PhaseIS,
  title={Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.},
  author={Eric K. Rowinsky and William A. Flood and Susan E. Sartorius and Meaghan Bowling and Johanna Wagner and David S. Ettinger},
  journal={Seminars in oncology},
  year={1995},
  volume={22 4 Suppl 9},
  pages={48-54}
}
Preliminary results of a phase I study of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), given by 3-hour infusion, followed by carboplatin in chemotherapy-naive patients with stage IV non-small cell lung cancer indicate that both agents can be combined at clinically relevant single-agent doses. The paclitaxel (mg/m2)/carboplatin area under the concentration-time curve (mg.min/mL) dose level of 225/7 is projected to be the maximally tolerated and recommended phase II dose level… CONTINUE READING